Strand Therapeutics has secured $153 million in a Series B financing round led by global investors including Kinnevik, Regeneron Ventures, Amgen Ventures, and Eli Lilly. The funding will support development of Strand’s mRNA-based therapies designed to program tumor cells to express immunostimulatory proteins, enhancing cancer immunotherapy efficacy. Early clinical data demonstrated safety and promising tumor shrinkage in advanced solid tumor patients. Strand’s approach utilizes messenger RNA to deliver programmable genetic circuits, aiming to overcome resistance to existing immunotherapies.